We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome.
- Authors
Héctor F Escobar-Morreale
- Abstract
OBJECTIVE: Osteoprotegerin (OPG), an inhibitor of osteoclastic bone resorption, has a variety of functions including anti-inflammatory effects and a possible cardiovascular protective role. Both low-grade chronic inflammation and cardiovascular risk are increased in women with the polycystic ovary syndrome (PCOS). We aimed to study serum OPG concentrations in PCOS patients. DESIGN: Case–control study including 40 PCOS patients matched with 40 non-hyperandrogenic women for age and body mass index. METHODS: Basal serum sampling and standard oral glucose tolerance test, and measurement of serum OPG concentrations by commercial ELISA. RESULTS: Serum OPG concentrations were lower in women with PCOS compared with those of controls (304±120 vs 363±105 pg/ml respectively; F=7.641, P=0.007) independently of obesity. No differences were observed in serum receptor activator of nuclear factor-κB ligand (RANKL) levels and in the RANKL/OPG molar ratio. A multivariate linear regression model (R2=0.208, F=6.579, P=0.001) showed that PCOS (β=–0.281, P=0.008), obesity (β=–0.245, P=0.022) and age (β=0.296, P=0.006) were predictive of serum OPG concentrations. CONCLUSIONS: Serum OPG concentrations are reduced in PCOS patients independently of obesity. Considering the anti-inflammatory effects of OPG, its reduced serum concentrations might contribute to the proinflammatory state and cardiovascular risk of PCOS patients.
- Subjects
POLYCYSTIC ovary syndrome; BONE resorption inhibitors; REGRESSION analysis; CARDIOVASCULAR diseases risk factors; OBESITY; ANTI-inflammatory agents; PATIENTS
- Publication
European Journal of Endocrinology, 2008, Vol 159, Issue 3, p225
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-08-0107